Wilson, Jo Ellen
Mart, Matthew F.
Cunningham, Colm
Shehabi, Yahya
Girard, Timothy D.
MacLullich, Alasdair M. J.
Slooter, Arjen J. C.
Ely, E. Wesley
Article History
Accepted: 29 September 2020
First Online: 12 November 2020
Change Date: 1 December 2020
Change Type: Correction
Change Details: An Erratum to this paper has been published: https://doi.org/10.1038/s41572-020-00236-z.
Competing interests
: C.C. acknowledges a current research collaboration with IONIS pharmaceuticals. Y.S. acknowledges unrestricted research grants from Pfizer, Orion Pharma, and Brainstem Biometrics and travel reimbursements and speaker honorarium for educational non-promotional symposia from Pfizer and Orion Pharma. A.J.C.S. is an adviser for Prolira, a start-up company that develops an EEG-based delirium monitor; any (future) profits from EEG-based delirium monitoring will be used for future scientific research only. A.M.J.M. is the main author of the 4AT delirium assessment tool (this tool is free to use and there is no financial interest) and holds patents for computerized delirium assessment tools (any future profits will be used for future scientific research only). E.W.E. received honoraria from Orion and Hospira for continuing medical education activity but does not hold stock or consultant relationships with these companies. The other authors declare no competing interests.
Free to read: This content has been made available to all.